Literature DB >> 14607828

Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs.

Yurong Lai1, Chung-Ming Tse, Jashvant D Unadkat.   

Abstract

Many antiviral drugs (e.g. fialuridine; FIAU) produce clinically significant mitochondrial toxicity that limits their dose or prevents their use in the clinic. Because the majority of nucleoside drugs is too hydrophilic to cross the highly impermeable mitochondrial membrane, we have hypothesized that they must be transported into the mitochondria to produce their toxicity. To test this hypothesis, we have sought to determine whether the nucleoside transporters, human equilibrative nucleoside transporter 1 (hENT1) or human concentrative nucleoside transporter 1 (hCNT1), when stably expressed in Madin-Darby canine kidney cells as yellow fluorescent fusion protein (YFP), are localized to the mitochondria. By using organelle-selective dyes and confocal microscopy, we have found that hENT1-YFP is localized to the mitochondria as well as the plasma membrane, whereas hCNT1-YFP was found predominantly on the plasma membrane. hENT1-YFP was not localized to the nuclear envelope, endosomes, lysosomes, or Golgi complex. Western blotting confirmed the presence of hENT1-YFP or endogenous hENT1 in mitochondria isolated from hENT1-YFP-expressing cells and human livers, respectively. In agreement with these localization data, [14C]FIAU was efficiently transported into the mitochondria of cells expressing hENT1-YFP but not of cells expressing hCNT1-YFP. The mitochondrial toxicity of FIAU to Madin-Darby canine kidney cells was enhanced by hENT1-YFP, even when hENT1 activity on the plasma membrane was selectively blocked by 10 nm nitrobenzylthioinosine. Moreover, FIAU (50 microm) produced significant mitochondrial toxicity ( approximately 70% decrease in mitochondrial DNA synthesis) when it was directly incubated with mitochondria isolated from hENT1-expressing cells. In conclusion, we have identified for the first time that hENT1 is expressed on the mitochondrial membrane and that this expression enhances the mitochondrial toxicity of nucleoside drugs such as FIAU. Mitochondrial expression of hENTs may explain the clinically significant mitochondrial toxicity caused by the anti-HIV nucleoside drugs such as zidovudine, stavudine, and didanosine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14607828     DOI: 10.1074/jbc.M307938200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

Review 1.  The role of transporters in the toxicity of nucleoside and nucleotide analogs.

Authors:  Christopher A Koczor; Rebecca A Torres; William Lewis
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-04-18       Impact factor: 4.481

2.  Inhibition of Transient Receptor Potential Channel Mucolipin-1 (TRPML1) by Lysosomal Adenosine Involved in Severe Combined Immunodeficiency Diseases.

Authors:  Xi Zoë Zhong; Yuanjie Zou; Xue Sun; Gaofeng Dong; Qi Cao; Aditya Pandey; Jan K Rainey; Xiaojuan Zhu; Xian-Ping Dong
Journal:  J Biol Chem       Date:  2017-01-13       Impact factor: 5.157

Review 3.  A cheminformatic toolkit for mining biomedical knowledge.

Authors:  Gus R Rosania; Gordon Crippen; Peter Woolf; David States; Kerby Shedden
Journal:  Pharm Res       Date:  2007-03-24       Impact factor: 4.200

4.  Zidovudine inhibits thymidine phosphorylation in the isolated perfused rat heart.

Authors:  Delia Susan-Resiga; Alice T Bentley; Matthew D Lynx; Darcy D LaClair; Edward E McKee
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

Review 5.  Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity.

Authors:  Brandon Swift; Nathan D Pfeifer; Kim L R Brouwer
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

Review 6.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

Review 7.  Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models.

Authors:  Richard J Weaver; Eric A Blomme; Amy E Chadwick; Ian M Copple; Helga H J Gerets; Christopher E Goldring; Andre Guillouzo; Philip G Hewitt; Magnus Ingelman-Sundberg; Klaus Gjervig Jensen; Satu Juhila; Ursula Klingmüller; Gilles Labbe; Michael J Liguori; Cerys A Lovatt; Paul Morgan; Dean J Naisbitt; Raymond H H Pieters; Jan Snoeys; Bob van de Water; Dominic P Williams; B Kevin Park
Journal:  Nat Rev Drug Discov       Date:  2019-11-20       Impact factor: 84.694

8.  Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches.

Authors:  Yingying Guo; Xiaoyan Chu; Neil J Parrott; Kim L R Brouwer; Vicky Hsu; Swati Nagar; Pär Matsson; Pradeep Sharma; Jan Snoeys; Yuichi Sugiyama; Daniel Tatosian; Jashvant D Unadkat; Shiew-Mei Huang; Aleksandra Galetin
Journal:  Clin Pharmacol Ther       Date:  2018-09-12       Impact factor: 6.875

Review 9.  Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics.

Authors:  Ankit Shah; Mohitkumar R Gangwani; Nitish S Chaudhari; Alexy Glazyrin; Hari K Bhat; Anil Kumar
Journal:  Neurotox Res       Date:  2016-06-30       Impact factor: 3.911

10.  Altered gene transcription profiles in fibroblasts harboring either TK2 or DGUOK mutations indicate compensatory mechanisms.

Authors:  Joan Villarroya; Carme de Bolós; Anna Meseguer; Michio Hirano; Maya R Vilà
Journal:  Exp Cell Res       Date:  2009-03-03       Impact factor: 3.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.